SSA
NBRV

Schonfeld Strategic Advisors’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$410K – 950
2017
Q3 		$410K Buy
+200
New +$469K 0.04% 407

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Schonfeld Strategic Advisors's NBRV Position: Q4 2017 in Review

Schonfeld Strategic Advisors sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2017, closing a stake of 200 shares — an estimated $410K sold.

Schonfeld Strategic Advisors first reported a position in NBRV in Q3 2017 and held it in 1 quarter. The position peaked at $410K in Q3 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q4 2017.

  • Schonfeld Strategic Advisors reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2017 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 200 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2017, an estimated $410K.
  • Schonfeld Strategic Advisors first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2017 and held it in 1 quarter.
  • Schonfeld Strategic Advisors's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $410K in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2017.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.